Saturday, 31 October 2026European Markets

ACCSYS Stock Over 28% Up In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of ACCSYS (AEX-Index: AXS.AS) jumped by a staggering 28.65% in 21 sessions from $0.75 to $0.97 at 13:11 EST on Monday, after two successive sessions in a row of losses. AEX-Index is dropping 1.5% to $752.40, after four consecutive sessions in a row of gains.

ACCSYS's last close was $0.98, 51.07% under its 52-week high of $2.01.

About ACCSYS

Accsys Technologies PLC, together with its subsidiaries, produces and sells solid wood and wood elements in the United Kingdom, Ireland, rest of Europe, the Americas, and internationally. It offers solid wood for use in windows, doors, decking, and cladding under the Accoya brand; and wood chips to manufacture panel products under the Tricoya brand. The company also provides technical and engineering services to licensees, as well as sales and marketing services; sells acetic acid; manufactures colored acetylated wood. Accsys Technologies PLC was incorporated in 2005 and is headquartered in London, the United Kingdom.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -36.45%.

More news about ACCSYS (AXS.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com